Cipla is currently trading at Rs. 932.10, up by 2.65 points or 0.29% from its previous closing of Rs. 929.45 on the BSE.
The scrip opened at Rs. 933.95 and has touched a high and low of Rs. 936.15 and Rs. 923.40 respectively. So far 50972 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 1005.00 on 29-Sep-2021 and a 52 week low of Rs. 738.25 on 19-Mar-2021.
Last one week high and low of the scrip stood at Rs. 936.15 and Rs. 881.10 respectively. The current market cap of the company is Rs. 75120.24 crore.
The promoters holding in the company stood at 36.12%, while Institutions and Non-Institutions held 45.83% and 18.05% respectively.
Cipla has been granted Emergency Use Authorisation (EUA) permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country. The company plans to launch Molnupiravir under the brand name Cipmolnu. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 at high risk of developing severe disease.
The company will soon make Cipmolnu 200 mg capsules available at all leading pharmacies and Covid treatment centers across the country. The company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
Tags : cipla share price, cipla tablet uses in hindi, cipladine, cipla tablet, cipla eas, cipla share, ciplar 10, cipladine uses in hindi, cipla tablet uses, cipla field call, cipla share price nse, cipla azithromycin, cipla anti dandruff shampoo, cipla annual report, cipla allergy tablet, cipla aerocort inhaler, cipla asthma pump, cipla asthalin, cipla amoxicillin 625, ciplar a 20, a to z capsule, vitamin a cipla,